###### Strengths and limitations of this study

-   This was the first study on the relationship between serum vitamin B~6~ (Vit B~6~) concentration and the status of bone mineral density (BMD) and bone turnover in the Asian population.

-   This was a cross-section study with limited strength.

-   No participants in this study were diagnosed as having Vit B~6~ deficiency; therefore, the risk of Vit B~6~ deficiency for osteoporosis could not be analysed.

-   For the sake of economic costs and limited time for on-site investigations, only lumbar spine BMD was measured in this study, which might lead to a certain degree of bias.

-   Other factors, which were not recorded in this study, may also have influences on serum vitamin concentrations and bone metabolism, such as medications affecting gastrointestinal absorption function, dietary intakes and physical activities.

Introduction {#s1}
============

Osteoporosis, a systemic skeletal disease, increases bone fragility and the risk of fracture by reducing bone mass and causing microarchitectural deterioration.[@R1] It is a growing health concern worldwide and the leading cause of fractures. Several risk factors for osteoporosis, such as age, obesity, smoking and drinking, have been identified.[@R2] Recently, studies have demonstrated that low dietary intake of vitamin B~6~ (Vit B~6~) or low blood Vit B~6~ concentrations might be a novel and potentially modifiable risk factor for osteoporosis.[@R3]

The vitamin B family includes thiamine (B~1~), riboflavin (B~2~), niacin (B~3~), pantothenic acid (B~5~), pyridoxine (B~6~), biotin (B~7~), folic acid or folate (B~9~) and cobalamin (B~12~).[@R5] Low levels of vitamin B~12~ and folate have been proved to be associated with low bone mineral density (BMD) and a higher risk of fractures in the elderly.[@R6] As a member of vitamin B family, Vit B~6~ is a water-soluble vitamin that is naturally present in many foods. Pyridoxine, pyridoxal, pyridoxamine and their phosphorylated derivatives are collectively/generically known as Vit B~6~. Vit B~6~ acts as a coenzyme in the metabolism of amino acids, carbohydrates, neurotransmitters and lipids, and it performs various functions in the body.[@R7]

An in vitro study of B-vitamins on the activity of human osteoclasts revealed that low concentrations of Vit B~6~ promoted osteoclast activity, thus indicating the role of low Vit B~6~ concentrations in bone degradation.[@R8] Vit B~6~ deficiency was reported to reduce new bone formation and cause an imbalance in the coupling between osteoblasts and osteoclasts in fracture healing in rats.[@R9] In addition, Vit B~6~ is an essential coenzyme for lysyl oxidase in collagen crosslinking.[@R10] Animal studies have shown that Vit B~6~ deficiency might impair crosslink formation, which subsequently adversely affects the mechanical properties of bones and contributes to bone fragility.[@R11] These preclinical studies have suggested crucial roles of Vit B~6~ in maintaining bone health.

Several observational studies have suggested that an inadequate dietary intake of Vit B~6~ or low plasma Vit B~6~ concentrations contribute to high bone loss, low BMD and a relatively high risk of osteoporotic fracture in older people,[@R3] whereas other studies have concluded that the incidence of osteoporosis and circulating Vit B~6~ concentration are not significantly associated.[@R13] Notably, almost all these studies were conducted in Western populations.[@R3] Because the dietary and lifestyle characteristics of Asian populations differ from those of Western populations,[@R14] no evidence is currently available on the association between serum Vit B~6~ concentrations and osteoporosis in Asian populations, particularly in the Chinese population.

Middle-aged and older people from Shanghai, China, with normal BMD, osteopenia and osteoporosis were recruited as participants for the present study. Serum Vit B~6~ concentrations, bone turnover marker concentrations and parameters related to calcium and phosphorus metabolism were measured. The relationship between the serum Vit B~6~ concentration and BMD and that between serum Vit B~6~ concentration and bone turnover marker concentrations were analysed.

Methods {#s2}
=======

Study design {#s2a}
------------

The present study was a cross-sectional study within the framework of an ongoing prospective population-based cohort study (clinical trial registration number NCT02958020). Residents from two subdistricts in Shanghai, China (Lujiazui subdistrict and Longhua subdistrict) participated in this study from July 2015 to February 2016. All the participants provided signed written informed consent prior to participation.

Inclusion and exclusion criteria {#s2b}
--------------------------------

*Inclusion criteria*: permanent residents of the aforementioned subdistricts (women aged ≥45 years and men aged ≥50 years), who agreed to provide signed written informed consent, were enrolled. *Exclusion criteria*: (1) residents with severe mental diseases or acute infectious diseases and who could not cooperate during the survey; (2) lactating or pregnant women; (3) premenopausal women because Z-scores, but not T-scores, are used for the diagnosis of osteoporosis among premenopausal women; (4) residents with severe physical diseases that affect bone metabolism or gastrointestinal absorption including chronic diarrhoea, severe liver dysfunction or renal failure, gastrectomy and enterectomy; (5) residents were taking vitamin D (Vit D), vitamin B or multivitamin supplements, or receiving medication that affected bone metabolism, including hormone drugs/hormonal replacement therapy and antiosteoporosis drugs.

Questionnaires and physical examinations {#s2c}
----------------------------------------

A total of 2285 residents were included in the survey. Data on the age, sex, height, body weight (in the standing position wearing indoor clothes without shoes), menopause, daily smoking frequency, daily alcohol consumption and ongoing medications of the participants were recorded. Body mass index (BMI) was calculated as weight (kg)/height squared (m^2^). After the execution of further screening, 456 residents were excluded because they were either taking Vit D, vitamin B or multivitamin supplements, or receiving medication that affected bone metabolism, including hormone drugs and antiosteoporosis drugs, at the time of the study. Finally, 1829 participants were enrolled for the final analysis.

Assessment of BMD and grouping {#s2d}
------------------------------

Lumbar spine BMD was evaluated as spine is the site of rapid bone loss.[@R16] When enrolled, the BMD of the lumbar spine (L1--L4) of the participants was measured using a dual-energy X-ray absorptiometry densitometer (Hologic Discovery CI, Bedford, Massachusetts, USA) and expressed as the T-score (number of SD above or below the mean BMD value at the patient's age or the mean BMD of healthy adults aged 30 years, respectively). The participants were divided into three groups, namely control, osteopenia and osteoporosis, according to the total BMD of the lumbar spine. Participants with T-scores ≥1.0 were included in the control group. Moreover, participants with T-scores between −1.0 and −2.5 were diagnosed as having osteopenia and included in the osteopenia group. Participants with T-scores ≤−2.5 were diagnosed as having osteoporosis and included in the osteoporosis group.

Serological detection {#s2e}
---------------------

Venous blood was drawn from all the participants in the morning after 10 hours of fasting. The serum samples were collected within 2 hours after the blood collection. The blood was gently mixed and centrifuged at 3000 rpm for 15 min at room temperature to separate the serum. The serum was immediately stored at 4°C and tested within 24 hours. Serum concentration of pyridoxal 5′-phosphate, one of the most salient active forms of Vit B~6~ in the body, was measured through high-efficiency liquid chromatography using an ultraperformance liquid chromatograph (Agilent 1290 Infinity, Santa Clara, California, USA).[@R18] The concentrations of osteocalcin (OST, 12149133122), β-C-terminal telopeptide of type I collagen (β-CTX, 11972308122) and N-terminal propeptide of type I collagen (PINP, 03141071190) were measured through an electrochemiluminescence immunoassay by using an automatic biochemical analyser (cobas 8000 e602, Roche, Basel, Switzerland). The concentration of alkaline phosphatase (ALP) was measured through a continuous monitoring technique by using an automatic biochemical analyser (modular P800, Roche). A sensitive and specific high-performance liquid chromatography-tandem mass spectrometry method executed using a liquid chromatography-tandem mass spectrometer (API4000, AB SCIX, Framingham, Massachusetts, USA) was applied to measure the concentrations of total serum 25(OH)D, including both 25(OH)D~3~ and 25(OH)D~2~.[@R19] The total concentrations of serum calcium and phosphorus were measured using the o-cresolphtalein-complexone method and through phosphomolybdate ultraviolet colorimetry, respectively, by using an automatic biochemical analyser (modular P800, Roche). The concentration of parathyroid hormone (PTH) (11972103160) was detected through a chemiluminescence immunoassay by using an automatic biochemical analyser (cobas 8000 e602, Roche). The concentration of fibroblast growth factor 23 (FGF23) was measured through an ELISA performed using a human FGF23 ELISA kit (CSB-E10113h, Cusabio Biotech, Wuhan, China) and a micro plate reader (MK3, Thermo, Waltham, Massachusetts, USA).

Inquirer quality assurance {#s2f}
--------------------------

All research assistants, interviewers and physical examiners were trained centrally by the professional epidemiologists and experienced staffs of the central coordinating centre over a 2-week period.

Statistical analyssis {#s2g}
---------------------

For baseline characteristics analysis, missing values were recorded as N/A and excluded from the final analysis using listwise deletion if the participants refused BMD assessment, physical examinations or part of the questionnaire. Sensitivity analysis was performed in case of missing values over 10% of the total values.

All statistical analyses were performed using SPSS V.19.0 (SPSS, Chicago, Illinois, USA). For all analyses, we categorised the participants into the osteoporosis, osteopenia and normal groups according to their lumbar BMD values. The distribution normality was tested using the Kolmogorov-Smirnov test. The Kruskal-Wallis test was used to compare non-normally distributed data between any two groups (normal, osteopenia and osteoporosis), according to the gender. Analysis of variance was used to compare the normal distribution data among the groups by gender. The Χ^2^ test was applied for the comparison of categorical variables. The associations between Vit B~6~ values and ranks of lumbar BMD (rank 0, normal, T-scores ≥1.0; rank 1, osteopenia, −2.5\<T scores \<−1; rank 2, osteoporosis, T-scores ≤2.5) were analysed using linear regression.

The values of serum Vit B~6~ concentrations were converted into ordinal quartiles, and a logistic regression model was used to examine the associations between values of the serum Vit B~6~ concentration quartiles and ranks of osteoporosis (rank 0, normal; rank 1, osteoporosis). We estimated the ORs and 95% CIs using the highest quartile as the reference category in multivariate models. The covariates included BMI, age, serum 25(OH)D concentration and serum PTH concentration.

We also examined the associations between serum Vit B~6~ concentrations and bone metabolism parameters, after additional adjustments for age and BMI, by using partial Pearson's correlation. All p values \<0.05 were considered to be statistically significant.

Patient and public involvement {#s2h}
------------------------------

The questionnaire was tested with participants. The outcomes of BMD and serum parameters were disseminated to the participants with printed reports. There was no other patient involvement in preparation or review of this study.

Results {#s3}
=======

The baseline characteristics of the participants in the control, osteopenia and osteoporosis groups are listed in [table 1](#T1){ref-type="table"}. Among the women, the mean age in the osteoporosis group was significantly increased than those in the control and osteopenia groups (p=0.000). Among the men, the mean age in the osteopenia group was lower than that in the control group (p=0.038). Among the men and women, the mean BMI values in the osteoporosis and osteopenia groups were significantly lower than that in control group (p=0.001 in women; p=0.000 in men). In addition, among the women, the BMI in the osteoporosis group was significantly lower than that in the osteopenia group (p=0.008). Meanwhile, the alcohol consumption and daily smoking frequencies did not differ significantly among the control, osteopenia and osteoporosis groups in the men and women (p\>0.05).

###### 

Comparison of baseline characteristics among control, osteopenia and osteoporosis groups

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Characteristics               Women (n=1206)       Men (n=623)                                                                                
  ----------------------------- -------------------- ---------------------- ----------------------- -------------------- ---------------------- -----------------------
  Age at screening (years)      61.5 (6.26)          62.0 (5.74)            64.7 (6.11)\*†          66.5 (5.84)          65.3 (6.19)\*          66.8 (6.37)

  BMI (kg/m^2^)                 25.4 (4.71)\         24.9 (9.79)\*\         23.4 (5.42)\*†\         24.9 (2.94)\         23.6 (2.68)\*\         23.0 (3.63)\*\
                                (n=327)              (n=526)                (n=310)                 (n=362)              (n=178)                (n=75)

  BMD (g/cm^2^), median (IQR)   1.02 (0.97--1.08)\   0.86 (0.82--0.90)\*\   0.71 (0.66--0.75)\*†\   1.13 (1.04--1.20)\   0.90 (0.87--0.94)\*\   0.75 (0.72--0.80)\*†\
                                (n=337)              (n=543)                (n=324)                 (n=365)              (n=179)                (n=75)

  Alcohol intake\               0.90\                2.00\                  0.70\                   12.1\                16.3\                  11.8\
  (\>1 drink per day) (%)       (n=319)              (n=507)                (n=302)                 (n=347)              (n=172)                (n=68)

  Current smokers (%)           2.20\                1.20\                  0.70\                   19.6\                24.2\                  25.0\
                                (n=315)              (n=509)                (n=305)                 (n=357)              (n=178)                (n=72)
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------

Data are expressed as mean (SD) unless indicated otherwise. Number of values for every single analysis was listed if there were missing values.

\*Compared with control group, p\<0.05.

†Compared with osteopenia group, p\<0.05.

BMD, bone mineral density; BMI, body mass index.

The median of serum Vit B~6~ concentration in the entire population was 22.00 µg/L (from 7.10 to 163.30 µg/L), with men showing 20.70 µg/L (from 7.10 to 163.30 µg/L) and women 22.80 µg/L (from 8.00 to 158.70 µg/L). [Table 2](#T2){ref-type="table"} presents the concentrations of serum Vit B~6~; concentrations of bone turnover markers, including serum PINP, β-CTX, OST and ALP and concentrations of serum calcium, phosphorus, 25(OH)D, PTH and FGF23 in the control, osteopenia and osteoporosis groups. The overall serum Vit B~6~ concentrations in the control, osteopenia and osteoporosis groups were similar in both men and women, although there were limited statistical significances between the osteoporosis group and other two groups in the women (compared with control group, p=0.028; compared with osteopenia group, p=0.017). Among the men, the serum Vit B~6~ concentrations did not differ significantly among the three groups (p\>0.05). Among the women, the concentrations of the bone turnover markers in the osteopenia and osteoporosis groups were evidently higher than those in the control group, including serum PINP (osteopenia vs control, p=0.000; osteoporosis vs control, p=0.000), β-CTX (osteopenia vs control, p=0.000; osteoporosis vs control, p=0.000), OST (osteopenia vs control, p=0.000; osteoporosis vs control, p=0.000) and ALP (osteopenia vs control, p=0.010; osteoporosis vs control, p=0.000); the concentrations of these bone turnover markers in the osteoporosis group were also higher than those in osteopenia group, including serum PINP (osteoporosis vs osteopenia, p=0.001), β-CTX (osteoporosis vs osteopenia, p=0.001), OST (osteoporosis vs osteopenia, p=0.013) and ALP (osteoporosis vs osteopenia, p=0.028). Furthermore, among the women, the serum 25(OH)D concentration in the osteoporosis group was significantly lower than the concentrations in the control and osteopenia groups (osteoporosis vs control, p=0.000; osteoporosis vs osteopenia, p=0.009). For men, the serum concentrations of PINP (p=0.002), β-CTX (p=0.000) and OST (p=0.003) in the osteoporosis group were also higher than those in the control group. In addition, most calcium and phosphorus metabolism markers, including calcium, phosphorus, serum 25(OH)D, PTH and FGF23, in the osteopenia and osteoporosis groups did not differ significantly from those in the control group (p\>0.05).

###### 

Comparison of serum Vit B~6~ and serological metabolism parameters among control, osteopenia and osteoporosis groups

  Characteristics   Women (n=1206)   Men (n=623)                                                    
  ----------------- ---------------- --------------- ---------------- ------------- --------------- ---------------
  Vit B~6~ (μg/L)   24.9 (8.90)      25.1 (11.4)     25.0 (14.0)\*†   23.3 (12.6)   23.8 (15.1)     22.4 (13.3)
  PINP (ng/mL)      42.8 (12.8)      48.6 (23.7)\*   52.3 (17.0)\*†   34.3 (13.9)   36.4 (12.8)     41.3 (18.5)\*
  β-CTX (ng/mL)     0.36 (0.12)      0.43 (0.17)\*   0.46 (0.16)\*†   0.30 (0.13)   0.34 (0.15)\*   0.39 (0.18)\*
  OST (ng/mL)       16.9 (4.88)      19.2 (6.59)\*   20.7 (7.36)\*†   14.2 (5.46)   14.9 (5.08)     16.3 (6.13)\*
  ALP (U/L)         75.9 (18.3)      79.3 (19.2)\*   83.2 (21.4)\*†   73.9 (19.9)   72.1 (18.9)     78.9 (27.4)
  P (mmol/L)        1.15 (0.13)      1.15 (0.13)     1.15 (0.13)      1.01 (0.19)   1.02 (0.15)     1.03 (0.19)
  Ca (mmol/L)       2.31 (0.09)      2.31 (0.10)     2.30 (0.09)      2.28 (0.09)   2.28 (0.10)     2.27 (0.11)‡
  25(OH)D (ng/mL)   18.7 (6.29)      18.2 (6.50)     17.0 (6.38)\*†   19.4 (6.74)   18.8 (6.35)     18.1 (6.22)
  PTH (pmol/L)      4.28 (1.54)      4.33 (1.60)     4.55 (1.88)      4.14 (1.46)   4.03 (1.53)     4.17 (1.67)
  FGF23 (pg/mL)     3.58 (7.66)      3.42 (6.19)     3.06 (6.89)      3.79 (6.30)   3.86 (6.08)     4.23 (11.3)

Data are expressed as mean (SD), analysed by Kruskal-Wallis test.

\*Compared with control group, p\<0.05.

†Compared with osteopenia group, p\<0.05.

‡Compared variance among the three group used analysis of variance test.

ALP, alkaline phosphatase; β-CTX, β-C-terminal telopeptide of type I collagen; Ca, calcium; FGF23, fibroblast growth factor 23; OST, osteocalcin; P, phosphorus; PINP, N-terminal propeptide of type I collagen; PTH, parathyroid hormone; Vit B~6~, vitamin B~6~.

The association between the risk of osteoporosis and low serum Vit B~6~ concentration in both men and women was analysed ([tables 3 and 4](#T3 T4){ref-type="table"}). Among the women, no significant linear trend was observed between the serum Vit B~6~ concentration and ranks of lumbar bone mass, before and after adjustment for age and BMI ([table 3](#T3){ref-type="table"}, p\>0.05). An analysis of the linear trend between the ordinal values of serum Vit B~6~ concentration quartiles and osteoporosis showed that a serum Vit B~6~ concentration in the first quartile (\<19.2 µg/L) was a risk factor for osteoporosis ([table 3](#T3){ref-type="table"}; without adjustment, OR=1.77, 95% CI 1.14 to 2.07, p=0.011, p\<0.05; after adjustment for age and BMI, OR=1.61, 95% CI 1.00 to 2.58, p*=*0.049, p\<0.05); however, no significant association between serum Vit B~6~ concentration and risk of osteoporosis was shown after adjustment with 25(OH)D and PTH, respectively ([table 3](#T3){ref-type="table"}; after adjustment for age, BMI and 25(OH)D, OR=1.35, 95% CI 0.83 to 2.22, p=0.231, p\>0.05; after adjustment for age, BMI and PTH, OR=1.54, 95% CI 0.95 to 2.49, p*=*0.078, p\>0.05). These findings suggested that women with relative low serum Vit B~6~ concentrations might be susceptible to osteoporosis, and the association depended on serum concentrations of 25(OH)D and PTH. Among the men, no significant linear trend was observed between serum Vit B~6~ concentrations and the ranks of lumbar bone mass. In addition, no significant linear trend was observed between the ordinal values of serum Vit B~6~ concentration quartiles and osteoporosis ([table 4](#T4){ref-type="table"}, p\>0.05).

###### 

OR (95% CI) for the risk of osteoporosis by quartiles of serum Vit B~6~ concentrations in women

  ---------------------------------------------------------------------------------------------------------------------------------------
                                              Model 1                 Model 2                 Model 3               Model 4
  ------------------------------------------- ----------------------- ----------------------- --------------------- ---------------------
  *p* ^1^ for linear trend                    0.88                    0.82                    0.28                  0.67

  Quartiles of Vit B~6~, μg/L                                                                                       

  *p* ^2^ for linear trend across quartiles                                                                         

   First quartile (\<19.2)\                   1.77 (1.14 to 2.07)\*   1.61 (1.00 to 2.58)\*   1.35 (0.83 to 2.22)   1.54 (0.95 to 2.49)
   (n=175)                                                                                                          

   Second quartile (19.2 to 22.8)\            1.55 (0.99 to 2.41)     1.46 (0.90 to 2.36)     1.27 (0.78 to 2.08)   1.42 (0.88 to 2.23)
   (n=171)                                                                                                          

   Third quartile (22.8 to 26.9)\             1.33 (0.85 to 2.07)     1.38 (0.85 to 2.22)     1.23 (0.75 to 2.00)   1.35 (0.83 to 2.18)
   (n=166)                                                                                                          

   Fourth quartile (\>26.9)\                  1                       1                       1                     1
   (n=150)                                                                                                          
  ---------------------------------------------------------------------------------------------------------------------------------------

*p* ^1^, linear regression based on serum Vit B~6~ values and ranks of lumbar bone mass (rank 0, normal; rank 1, osteopenia; rank 2, osteoporosis); *p* ^2^, OR (95% CI) test of linear trend based on logistic regression values of the Vit B~6~ quartiles and ranks of osteoporosis (rank 0, normal; rank 1, osteoporosis).

Model 1, unadjusted; model 2, multivariate adjustment by BMI and age; model 3, multivariate adjustment by BMI, age and 25(OH)D; model 4, multivariate adjustment by BMI, age and PTH.

\*P\<0.05.

BMI, body mass index; Vit B~6~, vitamin B~6~.

###### 

OR (95% CI) for the risk of osteoporosis by quartiles of serum Vit B~6~ concentrations in men

  -----------------------------------------------------------------------------------------------------------------------------------
                                              Model 1               Model 2               Model 3               Model 4
  ------------------------------------------- --------------------- --------------------- --------------------- ---------------------
  *p* ^1^ for linear trend                    0.59                  0.82                  0.91                  0.85

  Quartiles of Vit B~6~, μg/L                                                                                   

  *p* ^2^ for linear trend across quartiles                                                                     

  First quartile (\<17.5)\                    1.96 (0.92 to 4.17)   1.72 (0.79 to 3.74)   1.59 (0.72 to 3.52)   1.69 (0.77 to 3.70)
  (n=104)                                                                                                       

  Second quartile (17.5 to 20.7)\             1.63 (0.75 to 3.53)   1.54 (0.69 to 3.41)   1.45 (0.65 to 3.25)   1.52 (0.69 to 3.39)
  (n=112)                                                                                                       

  Third quartile (20.7 to 24.6)\              1.67 (0.77 to 3.61)   1.69 (0.73 to 3.63)   1.57 (0.70 to 3.52)   1.63 (0.73 to 3.63)
  (n=114)                                                                                                       

  Fourth quartile (≥24.6)\                    1                     1                     1                     1
  (n=113)                                                                                                       
  -----------------------------------------------------------------------------------------------------------------------------------

*p* ^1^, linear regression based on Vit B~6~ values and ranks of bone mass (rank 0, normal; rank 1, osteopenia; rank 2, osteoporosis); *p* ^2^, OR (95% CI) test of linear trend based on logistic regression values of the Vit B~6~ quartiles and ranks of osteoporosis (rank 0, normal; rank 1, osteoporosis).

Model 1, unadjusted; model 2, multivariate adjustment by BMI and age; model 3, multivariate adjustment by BMI, age and 25(OH)D; model 4, multivariate adjustment by BMI, age and PTH.

BMI, body mass index; Vit B~6~, vitamin B~6~.

The relationships between serum Vit B~6~ concentration and the markers of bone turnover and those between serum Vit B~6~ concentration and calcium and phosphorus metabolism in the different groups of women and men are listed in [table 5](#T5){ref-type="table"}. Notably, the serum Vit B~6~ concentration exhibited significant negative relationships with most of the bone turnover markers in the women in the osteoporosis group (PINP, p=0.008; OST, p=0.006 and β-CTX, p=0.028). Additionally, the serum Vit B~6~ concentration was significantly positively correlated with serum 25(OH)D concentrations in both women and men (women, control group, p=0.000 and osteoporosis group p=0.000; men, control group and osteoporosis group, p=0.000 and osteoporosis group p=0.008). The serum Vit B~6~ concentration in most groups was also significantly inversely related to the PTH concentration (women, control group, p=0.000 and osteoporosis group p=0.007; men, control group and osteoporosis group, p=0.003 and osteoporosis group p=0.034).

###### 

Relationship between serum Vit B~6~ concentrations and bone metabolism parameter concentrations in control, osteopenia and osteoporosis groups

            Correlation coefficient (women)   Correlation coefficient (men)                                    
  --------- --------------------------------- ------------------------------- ---------- ---------- ---------- ----------
  PINP      −0.008                            0.018                           −0.147\*   −0.040     −0.081     −0.061
  β-CTX     0.002                             0.001                           −0.122\*   −0.037     −0.082     −0.122
  OST       −0.022                            0.010                           −0.153\*   −0.069     −0.156\*   −0.132
  ALP       −0.092                            −0.117\*                        −0.085     −0.130\*   −0.079     −0.078
  P         0.179\*                           0.126\*                         0.039      0.092      0.062      0.131
  Ca        0.139\*                           0.017                           0.080      0.116\*    0.154\*    0.197
  25(OH)D   0.354\*                           0.233\*                         0.319\*    0.205\*    0.292\*    0.305\*
  PTH       −0.206\*                          −0.072                          −0.148\*   −0.155\*   −0.120     −0.245\*
  FGF23     −0.062                            −0.059                          −0.019     0.024      0.076      −0.038

P values of the relationship between serum Vit B~6~ concentrations and bone metabolism parameter concentrations.

\*P\<0.05.

ALP, alkaline phosphatase; β-CTX, β-C-terminal telopeptide of type I collagen; Ca, calcium; FGF23, fibroblast growth factor23; OST, osteocalcin; P, phosphorus; PINP, N-terminal propeptide of type I collagen; PTH, parathyroid hormone; Vit B~6~, vitamin B~6~.

Discussion {#s4}
==========

Relationships among serum vit B~6~ concentrations, reduced BMD and fracture {#s4a}
---------------------------------------------------------------------------

Vit B~6~ is widely distributed in plant-based foods such as beans, cereals and brown rice,[@R20] which are the most common components of the daily diet of the Chinese population, particularly in middle-aged and older people. An adequate supply of dietary Vit B~6~ sustains normal serum Vit B~6~ concentrations. Serum Vit B~6~ deficiency is defined as a serum Vit B~6~ concentration of \<20 nmol/L (4.94 µg/L).[@R21] Poor dietary intake or low circulating Vit B~6~ concentrations have been considered as a potential risk factor for osteoporosis; however, the relation of Vit B~6~ and BMD is debatable.

A longitudinal follow-up study of the Framingham Osteoporosis Study, in which \>22% of the participants were diagnosed as having serum Vit B~6~ deficiency, showed that bone loss was inversely associated with the serum Vit B~6~ concentration in older people, and people with serum Vit B~6~ deficiency exhibited lower femoral neck BMD values than did those with normal serum Vit B~6~ concentrations.[@R4] Therefore, Vit B~6~ deficiency might be a risk factor for decreased bone mass.

In our cross-sectional study on community-dwelling middle-aged and older people, we observed no significant differences in the serum Vit B~6~ concentrations among the control, osteopenia and osteoporosis groups; furthermore, we observed no linear trend between the serum Vit B~6~ concentrations and the ranks of lumbar bone mass. This finding is consistent with those of a previous study in postmenopausal British women.[@R15] In our study, the serum Vit B~6~ concentrations of all the female and male participants were \>7 µg/L, and the mean serum Vit B~6~ concentrations of all the groups were \>20 µg/L. The mean concentration of serum Vit B~6~ in postmenopausal British women was approximately 45 nmol/L (11.12 µg/L), which is also considerably higher than the limit of serum Vit B~6~ deficiency.

In this study, we found that the serum Vit B~6~ concentration in the lowest quartile, which was determined to be considerably higher than the limit of serum Vit B~6~ deficiency, might be a risk factor for osteoporosis in postmenopausal women. However, the association of serum Vit B~6~ was limited and dependent on serum 25(OH)D and PTH concentrations.

The Rotterdam study also showed that the risk of fracture decreased with an increase in dietary Vit B~6~ intake independent of BMD.[@R3] The Framingham Osteoporosis Study demonstrated that low plasma Vit B~6~ concentrations were associated with a high risk of fracture in older people.[@R4] Additionally, another study confirmed a statistically significant inverse relationship between dietary pyridoxine intake and hip fracture risk among women.[@R12] Both bone density and quality are crucial factors for determining bone strength, and collagen crosslinks play a crucial role in maintaining bone quality.[@R23] Vit B~6~ is essential for lysyl oxidase in collagen crosslinks,[@R10] and Vit B~6~ deficiency can reduce the concentrations of crosslinking intermediates and impair collagen crosslink formation in the bones,[@R24] thus leading to low bone quality. This could be a reason (apart from reduced BMD) for the observed association between high bone fracture risk and low dietary Vit B6 intake or low circulating Vit B6 concentrations.[@R3]

This cross-sectional study did not include participants with Vit B~6~ deficiency; therefore, the risk of Vit B~6~ deficiency for osteoporosis could not be analysed. In addition, only lumbar spine BMD was measured due to economic and time limits; other variables which were not involved in this study such as dietary intakes and physical activities could also influences the change the association of serum Vit B~6~ concentration and status of bone mass. All these limitations might lead to a certain degree of bias of this study.

Relationship between serum Vit B~6~ concentration and bone turnover marker concentrations in postmenopausal osteoporosis {#s4b}
------------------------------------------------------------------------------------------------------------------------

Postmenopausal osteoporosis occurs mainly due to the drastic reduction in endogenous oestrogen levels in women, which leads to an increase in the concentrations of circulating bone turnover markers. We found that the serum Vit B~6~ concentration was significantly inversely associated with the concentration of bone turnover markers in the women in the osteoporosis group. Low concentration of Vit B~6~ has demonstrated a stimulatory effect on osteoclast activity, although no significant effect on osteoclast number was revealed.[@R8] In addition, homocysteine (HCY) has been confirmed a significant correlation with bone resorption markers. High HCY level induced by low Vit B~6~ concentration, could stimulate bone resorption, leading to a shift of bone metabolism towards bone resorption.[@R27] This is consistent with our finding that the serum Vit B~6~ concentration was inversely associated with the concentration of bone resorption marker. Only a few studies have reported the relationship between serum Vit B~6~ and bone formation markers with equivocal results. Holstein *et al* found that the concentrations of serum OST were significantly lower in individuals with low serum Vit B~6~ concentrations than in those with high serum Vit B~6~ concentrations.[@R25] Also plasma OST and bone-specific ALP activity were significantly decreased in Vit B~6~-deficient animals.[@R28] In contrast, in vitro study with human primary osteoblasts found that decreasing B-vitamin concentrations was not accompanied by changes of ALP, OST, PINP as well as mineralised matrix formation.[@R29] It was reported that a decrease in bone resorption results in a rapid reduction in bone formation because of reduced release of coupling factors.[@R30] Therefore, there was possibly an indirect effect of serum Vit B~6~ on bone formation, which is secondary to its regulation on bone resorption. However, additional studies are still required to clarify the mechanisms by which Vit B~6~ affects bone turnover, especially bone formation, in menopausal osteoporotic women.

Relationship between serum Vit B~6~ concentration and 25(OH)D concentration and between serum Vit B~6~ concentration and PTH concentration {#s4c}
------------------------------------------------------------------------------------------------------------------------------------------

This study also showed that the serum Vit B~6~ concentration was significantly positively associated with the 25(OH)D concentration in the men and women, and it was inversely associated with the PTH concentration in all the women and men with normal bone mass or osteoporosis.

Serum 25(OH)D concentrations were significantly lower in animals with Vit D and Vit B~6~ deficiencies than in animals with Vit D deficiency alone. Recovery of serum 25(OH)D concentration after Vit D administration was delayed under conditions of Vit B~6~ deficiency.[@R31] Moreover, it was speculated that either the activity of renal 25-hydroxy-vitamin D-1-alpha-hydroxylase decreases or 1,25(OH)~2~D turnover increases in a state of Vit B~6~ deficiency.[@R28] Since serum Vit B~6~ might regulate Vit D metabolism, it was inferred that Vit B~6~ might indirectly regulate bone metabolism at least partially through its regulation on Vit D, which has dual effects on both bone formation and bone resorption.[@R32]

Thus far, studies have not revealed the regulatory effects of single Vit B~6~ on PTH expression. Vit D exerts negative feedback effects on PTH secretion to prevent the overcorrection of low calcium concentrations. On binding, the Vit D/Vit D receptor complex in parathyroid gland cells translocates into the nucleus and inhibits PTH transcription. Vit D can also inhibit PTH cell proliferation.[@R33] From our results, we infer that Vit B6 might play a positive role in Vit D metabolism, consequently prohibiting PTH secretion. However, the effects and regulatory mechanisms of Vit B~6~ on PTH are largely unknown.

Although the serum Vit B~6~ concentration was significantly associated with 25(OH)D and PTH, and both PTH and Vit D play critical roles in the maintenance of calcium and phosphate homeostasis and maintenance of bone health,[@R36] this study revealed no significant relationship between the serum Vit B~6~ concentration and the serum concentrations of calcium and phosphate. These findings are consistent with the results of a previous study, which showed that in rats with Vit B~6~ deficiency, Vit D metabolism was impaired without changes in plasma calcium homeostasis or BMD.[@R28]

Conclusion {#s5}
==========

In conclusion, a relatively low serum Vit B~6~ concentration might be a risk factor for osteoporosis in postmenopausal women, including those with normal serum Vit B~6~ concentrations. However, the contribution of relatively low serum Vit B~6~ concentration to osteoporosis risk was limited, and depended on serum concentrations of Vit D and PTH. Serum Vit B~6~ might play a potential role in postmenopausal osteoporosis.
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